Novavax (NVAX)

Executive Summary

Novavax is a biotechnology company specializing in protein-based vaccines using its recombinant nanoparticle technology. Its COVID-19 vaccine (NVX-CoV2373) received emergency use authorization but struggled with commercial uptake due to market saturation. The company is now refocusing on next-generation vaccines, including a combination COVID-19/influenza vaccine, an updated variant-specific COVID-19 booster, and a respiratory syncytial virus (RSV) vaccine. Financially, Novavax has implemented cost-cutting measures and secured manufacturing partnerships to extend its cash runway. Recent data from Phase 2 combo and RSV trials are encouraging, and the company aims to leverage its platform for seasonal respiratory vaccines. While near-term revenue remains pressured, the pipeline offers significant upside if clinical and regulatory milestones are met. Key risks include competitive landscape, manufacturing scale-up, and adoption in a post-pandemic market.

Upcoming Catalysts (preview)

• Q3 2026FDA authorization of updated COVID-19 booster targeting dominant variants for fall 2026 campaign70% success
• Q4 2026Phase 3 data readout for combination COVID-19/influenza vaccine (NanoFlu + COVID)60% success
• Q1 2027Regulatory submission or Phase 3 data for RSV vaccine in older adults50% success